PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer
- 24 November 2021
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 126 (5) , 778-790
Abstract
Background Castration-resistant prostate cancer (CRPC) patients frequently develop neuroendocrine differentiation, with high mortality and no effective treatment. However, the regulatory mechanism that connects neuroendocrine differentiation and metabolic adaptation in response to therapeutic resistance of prostate cancer remain to be unravelled. Methods By unbiased cross-correlation between RNA-sequencing, database signatures, and ChIP analysis, combining in vitro cell lines and in vivo animal models, we identified that PCK1 is a pivotal regulator in therapy-induced neuroendocrine differentiation of prostate cancer through a LIF/ZBTB46-driven glucose metabolism pathway. Results Upregulation of PCK1 supports cell proliferation and reciprocally increases ZBTB46 levels to promote the expression of neuroendocrine markers that are conducive to the development of neuroendocrine characteristic CRPC. PCK1 and neuroendocrine marker expressions are regulated by the ZBTB46 transcription factor upon activation of LIF signalling. Targeting PCK1 can reduce the neuroendocrine phenotype and decrease the growth of prostate cancer cells in vitro and in vivo. Conclusion Our study uncovers LIF/ZBTB46 signalling activation as a key mechanism for upregulating PCK1-driven glucose metabolism and neuroendocrine differentiation of CRPC, which may yield significant improvements in prostate cancer treatment after ADT using PCK1 inhibitors.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST109-2314-B-038-105, MOST109-2326-B-038-001-MY3, MOST110-2622-B-038-002)
- Taipei Medical University (110CM-TMU-07)
This publication has 40 references indexed in Scilit:
- Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady stateJournal of Experimental Medicine, 2012
- Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorSeminars in Oncology, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Metabolic sequelae associated with androgen deprivation therapy for prostate cancerCurrent Opinion in Endocrinology, Diabetes and Obesity, 2010
- Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular SenescenceCancer Cell, 2010
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 2008
- Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate CancerCancer Research, 2008
- Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and MetastasisCancer Research, 2008
- Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cellsOncogene, 2006
- Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplificationOncogene, 2005